Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs

ConclusionNSCLC patients represented genetically heterogeneous subgroup with a high frequency of co-occurring mutations in cancer-associated pathways. This diverse mutational profile may have key clinical and research implications for understanding the variability of treatment outcome in pre-TKI-treated NSCLC population. The differences in the MAF ofEGFR T790M may determine different responses to TKI therapy in patients harboring dual mutations.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research